Infinity Pharmaceuticals, Inc

Infinity Pharmaceuticals is an innovative cancer drug discovery and development company that specializes in small molecule drug technologies to bring new medicines to patients. The company s most-advanced drug candidate, IPI-504, is a proprietary, targeted cancer therapy that preferentially induces the death of cancer cells through the inhibition of the heat shock protein 90 complex. In preclinical animal studies of a wide variety of hematological malignancies and solid tumors, IPI-504 has demonstrated utility as both a single agent and in combination with other therapies. Infinity Pharmaceuticals owns all rights to the IPI-504 and commenced Phase I clinical trials in July 2005. The company also has an advanced drug candidate in IPI-609, another proprietary small molecule that operates through inhibition of the Hedgehog cell signaling pathway. Infinity also owns all rights to IPI-609. Since Infinity was founded in 2001, the company has raised more than $130 million from corporate partnerships and premier venture capitalists.